Atrium Therapeutics, Inc. (RNA)
7.84
-0.30
(-3.69%)
USD |
NASDAQ |
Oct 02, 16:00
7.98
+0.14
(+1.79%)
Pre-Market: 20:00
Atrium Therapeutics Enterprise Value : -128.42M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | -128.42M |
| October 01, 2026 | -123.29M |
| September 30, 2026 | -120.89M |
| September 29, 2026 | -118.50M |
| September 28, 2026 | -118.50M |
| September 25, 2026 | -120.72M |
| September 24, 2026 | -122.43M |
| September 23, 2026 | -120.04M |
| September 22, 2026 | -104.81M |
| September 21, 2026 | -105.32M |
| September 18, 2026 | -109.43M |
| September 17, 2026 | -98.99M |
| September 16, 2026 | -100.02M |
| September 15, 2026 | -89.93M |
| September 14, 2026 | -87.88M |
| September 11, 2026 | -85.31M |
| September 10, 2026 | -85.48M |
| September 09, 2026 | -82.74M |
| September 08, 2026 | -68.37M |
| September 04, 2026 | -19.79M |
| September 03, 2026 | -12.78M |
| September 02, 2026 | -22.02M |
| September 01, 2026 | -26.98M |
| August 31, 2026 | -34.68M |
| August 28, 2026 | -29.20M |
| Date | Value |
|---|---|
| August 27, 2026 | -23.39M |
| August 26, 2026 | -25.61M |
| August 25, 2026 | -23.04M |
| August 24, 2026 | -29.54M |
| August 21, 2026 | -36.73M |
| August 20, 2026 | -31.94M |
| August 19, 2026 | -28.00M |
| August 18, 2026 | -42.89M |
| August 17, 2026 | -40.83M |
| August 14, 2026 | -42.89M |
| August 13, 2026 | -51.61M |
| August 12, 2026 | -54.35M |
| August 11, 2026 | -52.64M |
| August 10, 2026 | -53.15M |
| August 07, 2026 | -51.44M |
| August 06, 2026 | -55.37M |
| August 05, 2026 | -61.70M |
| August 04, 2026 | -65.12M |
| August 03, 2026 | -68.72M |
| July 31, 2026 | -68.37M |
| July 30, 2026 | -66.49M |
| July 29, 2026 | -71.28M |
| July 28, 2026 | -65.98M |
| July 27, 2026 | -64.61M |
| July 24, 2026 | -65.98M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Tenax Therapeutics, Inc. | -54.72M |
| Exicure, Inc. | 5.613M |
| Century Therapeutics, Inc. | 195.19M |
| Absci Corp. | 1.702B |
| Celularity, Inc. | 114.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.19M |
| Revenue (Quarterly) | 3.004M |
| Total Expenses (Quarterly) | 23.19M |
| EPS Diluted (Quarterly) | -1.18 |
| Gross Profit Margin (Quarterly) | 88.58% |
| Profit Margin (Quarterly) | -672.0% |
| Earnings Yield | -58.77% |
| Normalized Earnings Yield | -58.77 |